Skip to content

Reducing relapse and recurrence in depression with continuation Cognitive Therapy: a randomized controlled trial.

Reducing relapse and recurrence in depression with continuation Cognitive Therapy: a randomized controlled trial. - Relapse prevention in depression.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40027
Enrollment
214
Registered
2012-01-30
Start date
2011-12-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive disorder

Interventions

Short-term continuation PCT (C-PCT) consist of 8 sessions that is offered as sequential treatment after response to A-CT. CT is directed at the identification of maladaptive cognitions and the devel

Sponsors

Arkin (Amsterdam)
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Two or more previous depressive episodes, 2. In remission according to DSM-IV criteria, 3. A current score of

Exclusion criteria

Exclusion criteria: 1. Current mania or hypomania or a history of bipolar illness, 2. Any psychotic disorder (current and previous), 3. Alcohol or drug misuse, 4. Predominant anxiety disorder, 5. Insufficient mastering of the Dutch language.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the cumulative proportion of relapses/recurrences in a survival-analysis over a follow-up period of 15 months after the start of the preventive therapy as measured with the *Structural Interview for DSM-IV (SCID) using the Longitudinal Interval Follow-up Evaluation (LIFE).

Secondary

MeasureTime frame
The secondary outcome variables are: 1. the severity of depressive symptoms as measured with the 'Inventory of Depression Symptomatology' (IDS-SR), and the *Hamilton Depression Rating Scale* (HDRS), 2. well-being, quality of life as measured with (EQ-5D), 3. social and interpersonal functioning as measured with the *Inventory of Interpersonal Problems* (IIP), 4. coping styles as measured with the *Utrecht Coping List* (UCL) 5. experienced negative life events as measured with the 'Brugha Questionaire' (Brugha) 6. personality disorder symptomatology as measured with the *Personality diagnostic questionnaire-revised* (PDQ-R) 7. level of psychological mindfulness as measured with the *Psychological Mindfulness Scale* (PMS) 8. sense of mastery as measured with the *Mastery scale* 9. consumption of mental health care and degree of work absence as measured with the *Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness* (TIC P) 10. identification of potential mediators and mechanisms of change using: a. coping styles as measured with the subscales *Active coping* and *Avoidance* of the *Utrecht Coping List* (UCL), b. social support as measured with the *Sociale Steun Lijst * Interacties* (SSL-I), c. acceptance and action as measured with the *Acceptance and Action Questionnaire* (AAQ), d. assessment of outcome as measured with the *Outcome Rating Scale* (ORS), e. the client*s perspective of the alliance with the therapist as measured with the *Session Rating Scale* (SRS), f. the severity of depressive symptoms as measured with the *Beck Depression Inventory* (BDI), g. working alliance as measured with the *Werk Alliantie Vragenlijst* (WAV-12), h. the intensity of dysfunctional attitudes as measured with the *Dysfunctional Attitude Scale* (DAS-17), i. the need for affiliation as measured with the *Affiliatie Lijst*, j. experienced daily stressors as measured with the *Daily Hassles Questionnaire*, k. positive and negative a

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)